AlloVir (NASDAQ:ALVR) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

AlloVir (NASDAQ:ALVRGet Rating) posted its quarterly earnings data on Thursday. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04, Fidelity Earnings reports.

AlloVir Trading Up 19.0 %

Shares of NASDAQ:ALVR opened at $7.76 on Friday. The stock has a market capitalization of $507.66 million, a PE ratio of -2.57 and a beta of 1.62. AlloVir has a 1 year low of $3.17 and a 1 year high of $26.41. The firm has a fifty day moving average price of $4.50 and a 200 day moving average price of $5.97.

Analysts Set New Price Targets

A number of research firms have commented on ALVR. Piper Sandler reduced their price objective on shares of AlloVir from $55.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, May 18th. SVB Leerink reduced their price target on shares of AlloVir from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, July 28th.

Insider Transactions at AlloVir

In related news, CEO Diana Brainard sold 29,135 shares of AlloVir stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $4.33, for a total transaction of $126,154.55. Following the transaction, the chief executive officer now directly owns 492,165 shares in the company, valued at $2,131,074.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other AlloVir news, insider Beek Jeroen B. Van sold 15,262 shares of the stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $4.40, for a total transaction of $67,152.80. Following the completion of the sale, the insider now directly owns 389,526 shares of the company’s stock, valued at approximately $1,713,914.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Diana Brainard sold 29,135 shares of the stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $4.33, for a total transaction of $126,154.55. Following the sale, the chief executive officer now directly owns 492,165 shares of the company’s stock, valued at $2,131,074.45. The disclosure for this sale can be found here. Insiders have sold a total of 50,571 shares of company stock worth $225,167 in the last ninety days. Insiders own 54.22% of the company’s stock.

Institutional Investors Weigh In On AlloVir

A number of institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in shares of AlloVir in the first quarter valued at $69,000. Goldman Sachs Group Inc. grew its holdings in shares of AlloVir by 16.7% in the first quarter. Goldman Sachs Group Inc. now owns 108,104 shares of the company’s stock valued at $730,000 after purchasing an additional 15,495 shares in the last quarter. PDT Partners LLC purchased a new position in shares of AlloVir in the first quarter valued at $204,000. Renaissance Technologies LLC bought a new stake in AlloVir in the first quarter worth $358,000. Finally, Federated Hermes Inc. bought a new stake in AlloVir in the first quarter worth $860,000. 38.73% of the stock is owned by hedge funds and other institutional investors.

About AlloVir

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

See Also

Earnings History for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.